“It costs about $2.5 billion to bring a drug to the market, and only about 30% of those actually succeed or meet their commercial goals when they get to the market.” Manufacturing leaders typically focus on the technical challenges directly
Carole Delauney warns that sterile injectable manufacturing “is not just fill-finish”—a misconception that can cost biotech companies millions and even derail entire drug development programs. She notes, “This is unfortunately not commonly recognized in the industry, but it is a
Artificial intelligence (AI) agents could dramatically accelerate clinical drug development, delivering 35 to 45 percent productivity gains across all clinical functions while cutting trial design timelines in half, according to a comprehensive analysis from McKinsey & Company. The consulting firm’s
